S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

ERNA Eterna Therapeutics Inc

0.3493

-0.0197 (-5.34%)

Jan 03 2025 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Eterna Therapeutics Charts.

Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Eterna Therapeutics Charts.

Eterna Therapeutics Inc News

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
Tuesday 3 December 2024 (1 month ago) • GlobeNewswire Inc.

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
Monday 25 November 2024 (1 month ago) • GlobeNewswire Inc.

Form 424B3 - Prospectus [Rule 424(b)(3)]
Monday 18 November 2024 (2 months ago) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Sunday 17 November 2024 (2 months ago) • Edgar (US Regulatory)

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
Thursday 14 November 2024 (2 months ago) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Tuesday 12 November 2024 (2 months ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 November 2024 (2 months ago) • Edgar (US Regulatory)

Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
Wednesday 30 October 2024 (2 months ago) • GlobeNewswire Inc.

Form 8-K - Current report
Tuesday 29 October 2024 (2 months ago) • Edgar (US Regulatory)

Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
Thursday 17 October 2024 (3 months ago) • GlobeNewswire Inc.

Form PRE 14A - Other preliminary proxy statements
Friday 27 September 2024 (3 months ago) • Edgar (US Regulatory)

More Eterna Therapeutics Inc News Articles

Global Developments (PK)

Anavex Life Sciences

Elite Pharmaceuticals (QB)

Rennova Health (CE)

Northwest Biotherapeutics (QB)

Fannie Mae (QB)

Lightwave Logic

Decentral Life (PK)

Asia Broadband (PK)

Digital Brand Media and ... (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions